The Orthopaedic Center, The First People's Hospital of Wenling, Taizhou University Affiliated Wenling Hospital, Wenling, Zhejiang, China.
College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, Hunan, China.
Front Immunol. 2024 May 16;15:1396122. doi: 10.3389/fimmu.2024.1396122. eCollection 2024.
As the world population ages, osteoporosis, the most common disease of bone metabolism, affects more than 200 million people worldwide. The etiology is an imbalance in bone remodeling process resulting in more significant bone resorption than bone remodeling. With the advent of the osteoimmunology field, the immune system's role in skeletal pathologies is gradually being discovered. The cytokine interferon-gamma (IFN-γ), a member of the interferon family, is an important factor in the etiology and treatment of osteoporosis because it mediates bone remodeling. This review starts with bone remodeling process and includes the cellular and key signaling pathways of bone remodeling. The effects of IFN-γ on osteoblasts, osteoclasts, and bone mass are discussed separately, while the overall effects of IFN-γ on primary and secondary osteoporosis are summarized. The net effect of IFN-γ on bone appears to be highly dependent on the environment, dose, concentration, and stage of cellular differentiation. This review focuses on the mechanisms of bone remodeling and bone immunology, with a comprehensive discussion of the relationship between IFN-γ and osteoporosis. Finding the paradoxical balance of IFN-γ in bone immunology and exploring the potential of its clinical application provide new ideas for the clinical treatment of osteoporosis and drug development.
随着世界人口老龄化,骨质疏松症作为最常见的骨骼代谢疾病,影响着全球超过 2 亿人。其病因是骨重建过程失衡,导致骨吸收比骨重建更为显著。随着骨免疫学领域的出现,免疫系统在骨骼病理学中的作用逐渐被发现。细胞因子干扰素-γ(IFN-γ)作为干扰素家族的一员,是骨质疏松症病因和治疗中的一个重要因素,因为它介导了骨重建。这篇综述从骨重建过程开始,包括骨重建的细胞和关键信号通路。分别讨论了 IFN-γ 对成骨细胞、破骨细胞和骨量的影响,同时总结了 IFN-γ 对原发性和继发性骨质疏松症的总体影响。IFN-γ 对骨的净效应似乎高度依赖于环境、剂量、浓度和细胞分化阶段。本综述重点关注骨重建机制和骨免疫学,全面讨论了 IFN-γ 与骨质疏松症的关系。在骨免疫学中寻找 IFN-γ 的矛盾平衡,并探索其临床应用的潜力,为骨质疏松症的临床治疗和药物开发提供了新的思路。